Abstract

Nimodipine Compounded Oral Suspension: A True Documented Medical Need

Author(s): McElhiney Linda F

Issue: Mar/Apr 2019 - Volume 23, Number 2

Page(s): 106-111

Download in electronic PDF format for $75

Abstract

What happens when there is an entire patient population, not just a specific patient, which cannot take a commercial product due to significant adverse effects, although the commercial product has a U.S. Food and Drug Administration-approved indication for the medical problem? What should or can be done in this situation? This article discusses this dilemma using a subarachnoid hemorrhage as an example of a true documented medical need, and discusses the option and circumstances surrounding the compounding of a nimodipine oral solution, a U.S. Food and Drug Administration–approved indication for the treatment of subarachnoid hemorrhages.

Related Keywords

Related Categories

Printer-Friendly Version

Related Articles from IJPC

Issue/Page View/Buy	Title/Author (Click for Abstract / Details / Purchase)
Mar/Apr 2019 Pg. 106-111	Nimodipine Compounded Oral Suspension: A True Documented Medical Need Author(s): McElhiney Linda F
Jul/Aug 2015 Pg. 303-305	U.S. Food and Drug Administration Proposed Guidance Document: Compounding Animal Drugs from Bulk Substances Author(s): Miller David G
Jul/Aug 2016 Pg. 351 View Sample	Discrepancies in the Law and the U.S. Food and Drug Administration Pharmacy Compounding Compliance Policy Guidelines Author(s): Allen Loyd V Jr
Sep/Oct 2017 Pg. 356	PreScription: 2017 Pharmacy Compounding Issues: The U.S. Food and Drug Administration, Harzardous Drugs, and Wasted Drugs Author(s): Allen Loyd V Jr
Sep/Oct 2013 Pg. 364-368	Preventing Medication Errors with Nimodipine by Compounding Proper Dosage Forms Author(s): McElhiney Linda F
Jan/Feb 2014 Pg. 65	Nimodipine 30-mg Capsules Author(s): Allen Loyd V Jr
Nov/Dec 2015 Pg. 487-488	U.S. Food and Drug Administration "Evaluation Criteria" for Difficult to Compound Drugs Author(s): Allen Loyd V Jr
Jul/Aug 2020 Pg. 296-297	Finally: A Final U.S. Food and Drug Administration Memorandum of Understanding, but It's Flawed Author(s): Brunner Scott
Jan/Feb 2017 Pg. 47-56	Basics of Sterile Compounding: Biopharmaceutics of Injectable Dosage Forms Author(s): Akers Michael J
Mar/Apr 2017 Pg. 95-102	U.S. Food and Drug Administration Inspections: Guide to a Successful Outcome for 503A Sterile Compounding Pharmacies Author(s): Yoch Doug
May/Jun 2014 Pg. 208	The U.S. Food and Drug Administration Responds to the International Academy of Compounding Pharmacists' Outsourcing Letter Author(s): Miller David G
Jan/Feb 2023 Pg. 22-23	The U.S. Food and Drug Administration Takes Aim at Compounded Thyroid Hormone Author(s): Brunner Scott
Sep/Oct 2015 Pg. 407	Nimodipine 3-mg/mL Oral Solution Author(s): Allen Loyd V Jr
Nov/Dec 2022 Pg. 516-521	Formulation Development of Modafinil Sprinkle Dosage Form: Study on the Effect of Food on Dosage Author(s): Kumaravelrajan Rajagopal, Karthik B, Venkatasan Suba
Nov/Dec 2023 Pg. 474-481	Nonsterile Basics of Compounding: Using U.S. Food and Drug Administration-approved Commercial Products as Ingredients Author(s): Allen Loyd V Jr
Jan/Feb 2019 Pg. 32-33	U.S. Food and Drug Administration Inspection Authority: How to Know Whether U.S. Food and Drug Administration Inspectors Are Crossing the Line Author(s): Snow Stephen T, Stannard Robert W, Bellis Jennifer, Moss Carrie A
Sep/Oct 2015 Pg. 389-390	Nominations of Difficult to Compound Drugs to the U.S. Food and Drug Administration--Pharmacy Compounding Advisory Committee: Part 1 Author(s): Allen Loyd V Jr
Nov/Dec 2016 Pg. 457-458	U.S. Food and Drug Administration List of Drugs NOT to be Used in Compounded Medications for Humans (The Negative List) Author(s):
Jul/Aug 2007 Pg. 326-327	Standard Operating Procedure: U.S. Food and Drug Administration Inspection--Releasing a Sample to the U.S. Food and Drug Administration Author(s): Kupiec Tom, Kemp Jesse
Nov/Dec 2020 Pg. 451-458	Safety Standards in Pharmaceutical Compounding, Part 3: Fire Safety Author(s): Allen W Chris, Greeson Nicole MH, Mixon William